预约演示
更新于：2026-08-26
JAB-8263
更新于：2026-08-26
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看时间轴
关联
3
项与 JAB-8263 相关的临床试验NCT07684157
A Phase Randomized, Double-blind, Placebo-controlled Evaluate the Efficacy and Safety IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
NCT04686682
A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors
NCT04587479
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Subjects With Advanced Solid Tumors
100 项与 JAB-8263 相关的临床结果
登录后查看更多信息
100 项与 JAB-8263 相关的转化医学
登录后查看更多信息
100 项与 JAB-8263 相关的专利（医药）
登录后查看更多信息
1
项与 JAB-8263 相关的文献（医药）World journal of gastrointestinal oncology
Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models
Article
作者: Yang, Gui-Qun ; Xia, Shao-You ; Long, Wei ; Du, Xiao-Hui ; Liu, Xin-Mo ; Li, Hai-Jun ; Li, Song-Yan ; Sun, Wen
BACKGROUND:
The overexpression of the MYC gene plays an important role in the occurrence, development and evolution of colorectal cancer (CRC). Bromodomain and extraterminal domain (BET) inhibitors can decrease the function BET by recognizing acetylated lysine residues, thereby downregulating the expression of MYC.
AIM:
To investigate the inhibitory effect and mechanism of a BET inhibitor on CRC cells.
METHODS:
The effect of the BET inhibitor JAB-8263 on the proliferation of various CRC cell lines was studied by CellTiter-Glo method and colony formation assay. The effect of JAB-8263 on the cell cycle and apoptosis of CRC cells was studied by propidium iodide staining and Annexin V/propidium iodide flow assay, respectively. The effect of JAB-8263 on the expression of c-MYC, p21 and p16 in CRC cells was detected by western blotting assay. The anti-tumor effect of JAB-8263 on CRC cells in vivo and evaluation of the safety of the compound was predicted by constructing a CRC cell animal tumor model.
RESULTS:
JAB-8263 dose-dependently suppressed CRC cell proliferation and colony formation in vitro. The MYC signaling pathway was dose-dependently inhibited by JAB-8263 in human CRC cell lines. JAB-8263 dose-dependently induced cell cycle arrest and apoptosis in the MC38 cell line. SW837 xenograft model was treated with JAB-8263 (0.3 mg/kg for 29 d), and the average tumor volume was significantly decreased compared to the vehicle control group (P < 0.001). The MC38 syngeneic murine model was treated with JAB-8263 (0.2 mg/kg for 29 d), and the average tumor volume was significantly decreased compared to the vehicle control group (P = 0.003).
CONCLUSION:
BET could be a potential effective drug target for suppressing CRC growth, and the BET inhibitor JAB-8263 can effectively suppress c-MYC expression and exert anti-tumor activity in CRC models.
55
项与 JAB-8263 相关的新闻（医药）2026-08-20
2026-08-20
100 项与 JAB-8263 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 类风湿关节炎 | 临床2期 | 中国 | 2026-06-30 | |
| 实体瘤 | 临床2期 | 中国 | 2022-01-30 | |
| 去势抵抗性前列腺癌 | 临床2期 | 中国 | 2021-05-07 | |
| 食管鳞状细胞癌 | 临床2期 | 中国 | 2021-05-07 | |
| 非小细胞肺癌 | 临床2期 | 中国 | 2021-05-07 | |
| 卵巢癌 | 临床2期 | 中国 | 2021-05-07 | |
| 难治性急性髓细胞白血病 | 临床2期 | 中国 | 2021-05-07 | |
| 小细胞肺癌 | 临床2期 | 中国 | 2021-05-07 | |
| 成人急性髓性白血病 | 临床1期 | 中国 | 2022-01-30 | |
| 骨髓纤维化 | 临床1期 | 中国 | 2022-01-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
PRNewswire 人工标引  | 临床1期 | 13 | 淵築鏇蓋鹹醖膚窪壓夢(膚衊鬱積簾糧夢齋鏇壓) = 膚衊構鏇遞衊構構餘網 網積積憲範顧壓醖構糧 (窪艱糧製網餘廠糧醖糧 ) 更多 | 积极 | 2025-01-08 | ||
(JAK inhibitors-treated) | 淵築鏇蓋鹹醖膚窪壓夢(膚衊鬱積簾糧夢齋鏇壓) = 鑰餘鹹鏇積遞廠齋糧齋 網積積憲範顧壓醖構糧 (窪艱糧製網餘廠糧醖糧 ) 更多 | ||||||
临床1期 | 16 | 鏇糧艱窪願夢製鑰鹹顧(鹹醖獵築顧壓餘襯選獵) = 醖積醖鏇鹹齋鏇築鹹膚 選壓顧醖鹽遞壓蓋選鬱 (衊鏇製構艱憲積願壓顧 ) 更多 | 积极 | 2024-12-08 | |||
patients treated with JAK inhibitors | 襯糧繭選壓獵願範鏇鑰(壓憲蓋衊齋遞鹽選鏇壓) = 顧壓鏇膚衊衊壓壓製糧 膚窪糧壓積憲繭襯鑰齋 (餘襯窪鏇積窪積蓋夢願 ) | ||||||
临床1/2期 | 28 | 糧範夢積膚齋積廠壓鹹(窪襯蓋鑰願糧廠鹽窪淵) = 構築鬱顧夢膚襯鬱選鹽 構齋構鹽醖顧構願壓鹹 (鏇築窪繭窪糧選壓醖範 ) 更多 | 积极 | 2024-05-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用